

# Dermatologic Surgery

Volume 33 Issue s1 Page S44-S50, January 2007

**To cite this article:** SÉRGIO TALARICO-FILHO MD, MAURÍCIO MENDONÇA DO NASCIMENTO MD, FERNANDO SPERANDEO DE MACEDO MD, CARLA DE SANCTIS PECORA MD (2007)

A Double-Blind, Randomized, Comparative Study of Two Type A Botulinum Toxins in the Treatment of Primary Axillary Hyperhidrosis

Dermatologic Surgery 33 (s1), S44–S50.

doi: 10.1111/j.1524-4725.2006.32331.x

[Prev Article](#) [Next Article](#)

**Full Text**

## A Double-Blind, Randomized, Comparative Study of Two Type A Botulinum Toxins in the Treatment of Primary Axillary Hyperhidrosis

- *SÉRGIO TALARICO-FILHO, MD\*\* All authors are affiliated with the Department of Dermatology, Universidade Federal de São Paulo-UNIFESP, Hospital São Paulo, São Paulo, Brazil,*
- *MAURÍCIO MENDONÇA DO NASCIMENTO, MD\*\* All authors are affiliated with the Department of Dermatology, Universidade Federal de São Paulo-UNIFESP, Hospital São Paulo, São Paulo, Brazil,*
- *FERNANDO SPERANDEO DE MACEDO, MD\*\* All authors are affiliated with the Department of Dermatology, Universidade Federal de São Paulo-UNIFESP, Hospital São Paulo, São Paulo, Brazil, AND*
- *CARLA DE SANCTIS PECORA, MD\*\* All authors are affiliated with the Department of Dermatology, Universidade Federal de São Paulo-UNIFESP, Hospital São Paulo, São Paulo, Brazil*

- \*All authors are affiliated with the Department of Dermatology, Universidade Federal de São Paulo-UNIFESP, Hospital São Paulo, São Paulo, Brazil

Address correspondence and reprint requests to: Sergio Talarico, MD, Rua Botucatu 448, 04023-061, São Paulo, Brazil, or e-mail: [talarico@cedermatarico.com.br](mailto:talarico@cedermatarico.com.br)

Allergan Pharmaceuticals Ltd. and Laboratórios Biosintética Ltd./Beaufour Ipsen Biotech furnished their products BOTOX and Dysport but had no interference in the study.

**Abstract**

**BACKGROUND** Botulinum toxin (BTX) is an effective treatment for primary axillary hyperhidrosis. In this study we used two toxins not bioequivalent: BOTOX (Allergan, Inc.) and Dysport (Beaufour Ipsen Biotech).

**OBJECTIVE** The objective was to compare the efficacy, safety, and tolerability of BOTOX and Dysport in the treatment of primary axillary hyperhidrosis using a conversion factor of 1:3, respectively.

**METHODS** In a double-blind, randomized prospective study, 10 patients with primary axillary hyperhidrosis and sweat production exceeding 50 mg/minute received 50 U of BOTOX in one axilla and 150 U of Dysport in the other. We performed Minor's test and gravimetry at 0 days, at 15 days, and monthly for 1 year.

**RESULTS** No significant difference was observed in the sweating quantity at baseline. After 1 month all patients had achieved success for both axillae. The sweat rate was reduced by a mean of 97.7% for BOTOX and 99.4% for Dysport, without statistical difference. The duration of benefits was similar between both toxins, with a mean of 260 days for BOTOX and 290 days for Dysport, without statistical difference. The longest symptom-free interval was 12 months (5 patients, 55.6%).

**CONCLUSIONS** BOTOX and Dysport presented similar levels of safety and efficacy in the treatment of primary axillary hyperhidrosis when a conversion factor of 1:3 was used.